poipotai	· ·
It is made available under a CC-B	Y 4.0 International license .

1	A risk stratification model for high-flow nasal cannula use in patients with coronavirus disease
2	2019 in Japan: a single-center retrospective observational cohort study
3	
4	Short title: A risk stratification model for severe COVID-19
5	
6	Ibuki Kurihara ^{1*} and Hitoshi Sugawara ¹
7	
8	¹ Division of General Medicine, Department of Comprehensive Medicine 1, Saitama Medical Center,
9	Jichi Medical University, Saitama City, Saitama, Japan
10	
11	* Corresponding author:
12	Ibuki Kurihara
13	Department of General Medicine, Saitama Medical Center, Jichi Medical University
14	1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama, 330-8503, Japan
15	Tel: +81-48-647-2111; Fax: +81-48-644-8617; E-mail address: hsmdfacp@jichi.ac.jp

17 Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic has put a strain on the
healthcare system, and sudden changes in disease status during home treatment have become a
serious issue. Therefore, prediction of disease severity and allocation of sufficient medical resources,
including high-flow nasal cannula (HFNC), to patients in need are important. We aimed to determine
risk factors for the need of HFNC use in COVID-19.

23 Methods: This was a single-center retrospective observational cohort study including all eligible

hospitalized adult patients aged \geq 18 years diagnosed with COVID-19 between April 14, 2020 and

August 5, 2021 who were treated in the study hospital. The primary outcome was critical respiratory

26 illness meeting one of the following criteria: oxygenation flow rate \geq 10 L/min, high-flow

27 oxygenation, noninvasive ventilation, invasive ventilation, and death. Nineteen potential predictive

variables, including patient characteristics at hospital admission, were screened using least absolute

shrinkage and selection operator and logistic regression to construct a predictive risk score. Accuracy

30 of the risk score was determined using area under the receiver operating characteristic curve.

31 **Results:** The study cohort included 148 patients. The rate of critical respiratory illness was 22.9%

32 (all patients needed high-flow device support). Among the 19 potential variables, percutaneous

33 oxygen saturation (SpO₂) <92% (odds ratio [OR] 7.50, 95% confidence interval [CI] 2.806–20.82)

and IL-6 (OR 1.021, 95% CI 1.010–1.033) were included in developing the risk score, which was

35 termed interleukin (IL)-6-based COVID-19 severity (IBC-S) score.

Conclusions: The IBC-S score, an easy-to-use risk score based on parameters available at the time of hospital admission, predicted critical respiratory failure in patients with COVID-19. In primary care settings, the IBC-S score based on interleukin-6 and SpO2 might aid in determining patients who should be transported to a tertiary medical institution or an isolation facility.

41 Introduction

The coronavirus disease 2019 (COVID-19) pandemic has claimed approximately 15 million lives as 42of September 2022 [1]. While approximately 80% of patients with COVID-19 experience a mild 43disease course and recover, the remaining 20% of the infected patients rapidly progress to severe 44COVID-19 [2] High-flow nasal cannula (HFNC) can deliver high concentrations of humidified 45oxygen with low positive end-expiratory pressure and facilitate the elimination of carbon dioxide, 46 47thereby rapidly relieving the symptoms of acute hypoxemic respiratory failure [3]. In the COVID-19 pandemic, HFNC use significantly reduced the need for mechanical ventilation support and 4849shortened the time to clinical recovery compared with conventional low-flow oxygen therapy [4]; therefore, HFNC has been played an important role in the management of patients with severe or 50critical COVID-19 [5]. However, HFNC uses hyperbaric oxygen, which limits the medical facilities 5152that can utilize it. In Japan, the COVID-19 pandemic has put a strain on the healthcare system and the sudden change 53in disease status during home treatment has become a serious problem [6]. Therefore, predicting the 54severity of COVID-19 and allocating sufficient medical resources, including HFNC, to patients in 55need are important. Therefore, we aimed to determine the risk factors for HFNC use in patients with 56COVID-19 by examining the medical records of patients treated in our medical center during the 57COVID-19 Alpha, Beta, and Delta surges in Japan. 58

59

60 Materials and Methods

61 Study design, participants, and setting

62 This was a single-center retrospective observational cohort study including all adult patients aged

 $63 \ge 18$ years that were diagnosed with COVID-19 and hospitalized in the Division of General Medicine,

64 Saitama Medical Center, Jichi Medical University between April 14, 2020 and August 5, 2021. The

65 study period covered the COVID-19 Alpha, Beta, and Delta surges in Japan.

66 Primary outcome, data collection, and processing

The primary outcome was critical respiratory illness meeting one of the following criteria any time after the day of admission: oxygenation flow rate ≥ 10 L/min, high-flow oxygenation, noninvasive ventilation, invasive ventilation, and death [7]. In all patients, the COVID-19 diagnosis was confirmed based on a positive nucleic acid amplification test using oropharyngeal, nasopharyngeal, or oropharyngeal/nasopharyngeal swab samples. The study data were collected from electronic medical records between September 15, 2021 and March 31, 2023.

73 Sample size estimation

74 G*Power version 3.1.9.2 (Heinrich Heine University Duesseldorf, Duesseldorf, Germany) was used

to determine the required sample size using the following parameters: test family, z test; statistical

test, logistic regression; type of power analysis, a priori: compute required sample size—given α ,

power, and effect size; tails, two; odds ratio, 8.142 (alternative hypothesis was assumed to be

moderately correlated at 0.3, and null hypothesis was assumed to be 0.05); α error probability, 0.05;

power (1 – β error probability), 0.8; R² other X, 0.26 (i.e., the regression equation is accurate.); X

distribution, exponential; X parm λ , 0.3. The calculated sample size was 44.

81 **Potential predictive variables**

82 We referred to the previous studies and extracted potential predictive variables [2,8,9]. Potential

83 predictive variables were patient characteristics at the time of hospital admission and included

84 demographic variables (age, sex, and smoking status), medical history (diabetes mellitus,

85 hypertension, coronary artery disease, chronic kidney disease, chronic heart failure, and cancer),

86 physical parameters (body mass index and percutaneous oxygen saturation [SpO₂]), laboratory

87 parameters (lymphocyte count, C-reactive protein, albumin, direct bilirubin, lactate dehydrogenase,

88 ferritin, D-dimer, and interleukin 6 [IL-6]), and prehospital treatments (steroid, remdesivir,

89 tocilizumab, and baricitinib).

90 Ethics approval

The current study was approved by the Institutional Clinical Review Board of Saitama Medical Center, Jichi Medical University (approval no: Clinical # S21-024). In accordance with the ethical guidelines for medical and health research involving human subjects in Japan, written informed consent was not required due to the retrospective study design. The study was conducted with the online opt-out method accessed through the hospital website.

96 Statistical analysis

97 The 19 potential predictive variables were entered into analysis to construct a predictive risk score for HFNC use. The Mann–Whitney U and Pearson's chi-square tests were used to compare 98 99continuous and categorical baseline characteristics, respectively. The least absolute shrinkage and selection operator method was used to minimize the potential collinearity of variables from the same 100 patient and the over-fitting of variables. Imputation for missing variables was considered if missing 101102values were lower than 20%. The selected variables and treatment before admission which was a 103confounder, were included in the multiple logistic regression analysis. The predictive value of risk stratification models was assessed using area under the receiver operating characteristic curve. For 104continuous variables included in the model, parameter values with the equal sensitivity and 105106 specificity and the highest positive predictive value were chosen as cut-off values [10]. After the creation of the risk scoring model using the selected variables, bootstrapped logistic regression was 107 used to verify internal validity. All statistical tests were two-tailed with significance set at a P value 108 109 of < 0.05.

The Stata/SE 16.2 software (StataCorp, College Station, TX, USA) was used for all
statistical analyses.

112

- 113 **Results**
- 114 **Baseline information of the participants**

115	The study flow chart is shown in Fig 1. During the study period, a total of 152 patients were admitted
116	with COVID-19 in the study institution. The actual study cohort size was markedly above the
117	estimated sample size (152 versus 44), which increased the power of the study. Of these 152 patients,
118	4 patients who met the primary study endpoint of critical respiratory illness on the day of admission
119	were excluded; therefore, the final analysis included 148 patients.
120	
121	Fig 1 Study flow diagram
122	PCO; primary composite outcome; COVID-19, coronavirus disease 2019
123	
124	Table 1 shows the demographic and clinical characteristics of the cohort. Briefly, the
125	median age (interquartile range) was 58.5 (23-84) years, 43 patients (30%) of the patients were
126	female, and 18.4% of the patients had at least one comorbidity. Of the 148 patients, 34 patients
127	(22.9%) required oxygen with a flow rate of ≥ 10 L/min, 34 patients (22.9%) required high-flow
128	device support, 9 (6.1%) patients required invasive ventilation, and 13 patients (8.8%) died.
129	Additionally, 12 patients (8.1%) were admitted to the intensive care unit after the day of admission.

Table 1. Baseline patient characteristics

	Total patients (n =			Р
	148)	Outcome $(n = 34)$	Non-outcome ($n = 114$)	value
Age	58.5 (23-84)	60 (44–89)	57.5 (22–83)	0.037
Male, n (%)	105 (70%)	25 (73.5%)	80 (70.1%)	0.705
BMI (kg/m ²)	24.69 (17.9–33.5)	25.1 (16.8–33.3)	24.6 (17.9–33.8)	0.521
Diabetes, n (%)	51 (34.4%)	18 (52.9%)	33 (28.9%)	0.01

Hypertension, n (%)	77 (52.0%)	25 (73%)	52 (45.6%)	0.004
Ever smoker, n (%)	71 (48.3%)	14 (41.1%)	57 (50.4%)	0.343
Coronary artery disease, n (%)	11 (7.4%)	4 (11.7%)	7 (6.1%)	0.272
Chronic heart failure, n (%)	6 (4.0%)	3 (8.8%)	3 (2.6%)	0.108
Chronic kidney disease, n (%)	16 (10.8%)	4 (11.76%)	12 (10.5%)	0.838
SpO ₂ on room air <92%, n (%)	70 (47.3%)	28 (82.3%)	42 (36.8%)	0
Malignancy, n (%)	28 (18.9%)	6 (17.6%)	22 (19.3%)	0.829
Laboratory tests				
Albumin (g/dL)	3.6 (2.5–4.5)	3.4 (1.9–4)	3.7 (2.6–4.5)	0.001
D-bil (mg/dL)	0.2 (0.1–0.64)	0.24 (0.12–0.87)	0.19 (0.1–0.55)	0.029
LDH (U/L)	296 (146–541)	358 (214–591)	264 (143–541)	0
CRP (mg/dL)	3.95 (0.09–20.14)	7.65 (0.76–29.2)	2.94 (0.06–14.2)	0
Lymphocyte(/µL)	804 (294–1938)	516 (172–1286)	891 (392–2172)	0
Ferritin (ng/mL)	359 (60–1486)	467 (139–1769)	310 (51–1486)	0.014
D-dimer (µg/mL)	1.15 (1-4.8)	1.4 (1–5.1)	1.1 (1-4.8)	0.038
IL-6 (pg/mL)	15 (2.2–139)	31.7 (5.6–186)	13.05 (1.3–65.5)	0
Therapy before-admission				
Steroids, n (%)	25 (16.8%)	10 (29.41%)	15 (13.16%)	0.026

medRxiv preprint doi: https://doi.org/10.1 preprint (which was not certified by pe	101/2023.08.20.23294344; t eer review) is the author/fund perpetui made available under a CC-f	his version posted August 2 der, who has granted medR: ity. 3Y 4.0 International license	1, 2023. The copyright hold xiv a license to display the	ler for this preprint in
Remdesivir, n (%)	6 (4.0%)	4 (3.5%)	2 (5.88%)	0.538
Tocilizumab, n (%)	0	0	0	
Baricitinib, n (%)	1 (0.68%)	1 (0.88%)	0 (0.0%)	0.534

Continuous data are shown as medians with interquartile ranges.

The Mann-Whitney and Pearson's chi-square tests were used.

BMI, body mass index; SpO₂, oxygen saturation; D-bil, direct bilirubin; LDH, lactate dehydrogenase; CRP,

C-reactive protein; IL-6, interleukin-6

130

131 Selection of predictors

- 132 A total of 19 variables that were measured at the time of admission were included in the least
- 133 absolute shrinkage and selection operator regression, which identified SpO₂ and IL-6 as significant
- 134 predictors of critical respiratory illness. In the logistic regression model including these two
- parameters, both an SpO₂ <92% (odds ratio [OR] 7.50, 95% confidence interval [CI] 2.806–20.82; P
- 136 < 0.001) and IL-6 (per 10 pg/ml increase, OR 1.23, 95% CI 1.010–1.038; P < 0.001) were
- 137 independent and significant predictors of critical respiratory illness and were included in the risk
- 138 score (Table 2).

Table 2 Association of SpO2 <92% and IL-6 with the risk of critical respiratory illness

Crude		Multivariable-adjusted	
OR (95% CI)	P value	OR (95% CI)	P value

SpO ₂ <92%	8.00 (3.06–20.9)	<0.001	7.50 (2.80–20.0)	< 0.001
IL-6 (per 10 pg/mL increase)	1.19 (1.07–1.32)	0.001	1.23 (1.10–1.38)	< 0.001

Logistic regression models were used to estimate odds ratios, 95% confidence intervals, and P values.

The multivariable logistic regression model included two likely confounders: before-admission therapy with steroids and remdesivir.

SpO₂, oxygen saturation; IL-6, interleukin-6; CI, confidence interval; OR, odds ratio

139

140 **Construction of the risk score**

- 141 The cut-off IL-6 value of 19.5 pg/mL exhibited equal sensitivity and specificity with the highest
- 142 positive predictive value of 63.2 pg/mL; therefore, this value was used to create the IL-6-based
- 143 COVID-19 severity [IBC-S] score to determine the risk of critical respiratory failure (Table 3). The
- 144 IBC-S risk score ranged from 0 to 3.

Table 3 IL-6 based COVID-19 severity score to predict the critical respiratory illness

Variable	IBC-S score
SpO ₂ on room air (%)	
≥92	0
<92	1
IL-6 (pg/mL)	
<19.5	0

19.5–63.2	1
63.2	2

IBC-S, interleukin-6-based COVID-19 severity; SpO₂, oxygen saturation; IL-6, interleukin-6.

145

146 **Performance of the risk score**

147 The bootstrap analysis for internal validation indicated that the mean area under the receiver

operating characteristic curve based on the cohort data was 0.834 (OR 4.762, 95% CI 2.198–10.31; P

149 < 0.001). An IBC-S score of < 1 had a sensitivity of 93.94% and a negative likelihood ratio of 0.13.

150 An IBC-S score of >3 had a specificity of 98.15% and a positive likelihood ratio of 19.63 (Table 4).

Table 4 Performance of the IBC-S score

Cut-off value	Sensitivity (%)	Specificity (%)	Positive likelihood ratio	Negative likelihood ratio
≤1	93.9	43.5	1.66	0.13
≥3	36.3	98.1	19.6	0.64

151

152 **Discussion**

Early identification of patients with COVID-19 at increased risk for HFNC use is beneficial for the
proper use of medical resources. In the present study, we found that the combination of SpO₂ and
IL-6 at admission may predict critical respiratory illness in patients hospitalized with COVID-19.
Simple risk scoring strategies are important in primary care settings. The IBC-S score

157 provides a simple assessment approach based on a small number of predictor variables determined at

158 the time of admission. The IBC-S score has only two predictor variables; in comparison, the 4C

mortality score has eight predictor variables and the COVID-GRAM score has ten predictor
variables [2,11]. Moreover, the IBC-S score requires only physical examination findings and the
measurement of IL-6 and does not require medical history, blood gas tests, or imaging studies. In the
COVID-19 era, simple risk scores are important since imaging studies and more sophisticated tests
may not be available in many situations.

SpO₂ is one of the two variables of the IBC-S score. The main pathologic feature of COVID-19 is viral pneumonia with alveolar edema and blockage of small bronchi, leading to the compromise of pulmonary gas exchange and reduced oxygen saturation, which is a major indicator of disease severity [12]. Since arterial blood gas analysis is an invasive and complex test, SpO₂ measurement is more frequently used to estimate the arterial oxygen partial pressure in primary care settings [13]. A study previously reported SpO₂ as one of the predictors of inpatient mortality in patients with COVID-19 [12]. SpO2 is one of the preeminent predictors of severe COVID-19.

171High IL-6 levels are a predictor of severe COVID-19. IL-6 is a cytokine in cell signaling 172and the regulation of immune cells. IL-6 has a strong proinflammatory effect with multiple biologic 173functions and plays an important role in inflammation [14]. In patients with COVID-19 complicated 174by acute respiratory distress syndrome, hyperactivation of the immune system with prominent IL-6 response can lead to organ dysfunction [9]. Several systematic reviews and meta-analyses revealed 175that IL-6 inhibitors such as tocilizumab were associated with reduced mortality in patients with 176177COVID-19 [9,15]. In one systematic review and meta-analysis [9,15], IL-6 was one of the predictors 178of ventilator management and death [9,15][NO PRINTED FORM]. In primary care settings, the evaluation of IL-6 and SpO₂ may aid in identifying patients who should be transported to an 179180 appropriate medical institution or an isolation facility.

181 The present study has several limitations that should be acknowledged. First, the external 182 validity of the IBC-S score was not tested and future studies using other cohorts are warranted to 183 confirm its validity. Second, the study population did not include patients infected with the Omicron

184variants, which have been increasing in prevalence worldwide [16]. Several Omicron subvariants exhibit replication advantage over prior variants [17] and can evade human immunity to a greater 185extent than the prior variants [18]. Additionally, the Omicron subvariants might be associated with 186187less severe disease than the other variants [19]. Zhang et al. reported that an SpO₂ of <90% was associated with critical illness in [20] patients infected with the Omicron variant, although the 188association of IL-6 with disease severity was not investigated [20]. It is possible that the IBC-S score 189 might show different results in the evaluation of patients infected with the Omicron variant. Finally, 190 the current study cohort did not include patients who were vaccinated. Future studies should consider 191 192evaluating the utility of the IBC-S score in other cohorts including those infected with other variants and those who are vaccinated. . 193

194

195 **Conclusions**

The IBC-S score, an easy-to-use risk score based on parameters that can be obtained at the time of hospital admission, predicted critical respiratory failure. In primary care settings, the evaluation of IL-6 and SpO₂ might aid in determining patients who should be transported to a tertiary medical institution or an isolation facility.

200

201 List of abbreviations

- 202 COVID-19, coronavirus disease 2019
- 203 HFNC, high-flow nasal cannula
- 204 SpO₂, percutaneous oxygen saturation

```
206 Acknowledgments
```

207	We would li	ke to thank Drs. Takahiko Fukuchi, Hiroshi Hori, and Hanako Yoshihara for their
208	medical care	e of the study participants. We also thank Enago for providing English proofreading
209	services.	
210		
211		References
212	1.	Barouch DH. Covid-19 vaccines — immunity, variants, boosters. N Engl J Med.
213		2022;387: 1011-1020. doi: 10.1056/NEJMra2206573.
214	2.	Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of
215		patients admitted to hospital with covid-19 using the ISARIC WHO clinical
216		characterisation protocol: Development and validation of the 4C mortality score. BMJ.
217		2020;370: m3339. doi: 10.1136/bmj.m3339.
218	3.	Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen
219		through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372:
220		2185-2196. doi: 10.1056/NEJMoa1503326.
221	4.	Ospina-Tascón GA, Calderón-Tapia LE, García AF, Zarama V, Gómez-Álvarez F,
222		Álvarez-Saa T, et al. Effect of high-flow oxygen therapy vs conventional oxygen
223		therapy on invasive mechanical ventilation and clinical recovery in patients with severe
224		COVID-19: A randomized clinical trial. JAMA. 2021;326: 2161-2171. doi:
225		10.1001/jama.2021.20714.

226	5.	Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ. Rational use of face masks in the
227		COVID-19 pandemic. Vol. 8, In: The lancet respiratory medicine. London: Lancet
228		Publishing Group; 2020. pp. 434-436. doi: 10.1016/S2213-2600(20)30134-X.
229	6.	Terada M, Ohtsu H, Saito S, Hayakawa K, Tsuzuki S, Asai Y, et al. Risk factors for
230		severity on admission and the disease progression during hospitalisation in a large
231		cohort of patients with COVID-19 in Japan. BMJ Open. 2021;11: e047007. doi:
232		10.1136/bmjopen-2020-047007.
233	7.	Haimovich AD, Ravindra NG, Stoytchev S, Young HP, Wilson FP, van Dijk D, et al.
234		Development and validation of the quick COVID-19 severity index: A prognostic tool
235		for early clinical decompensation. Ann Emerg Med. 2020;76: 442-453. doi:
236		10.1016/j.annemergmed.2020.07.022.
237	8.	Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a
238		clinical risk score to predict the occurrence of critical illness in hospitalized patients
239		with COVID-19. JAMA Intern Med. 2020;180: 1081-1089. doi:
240		10.1001/jamainternmed.2020.2033.
241	9.	Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and
242		meta-analysis. Vol. 30, In: Reviews in medical virology. New York: John Wiley and
243		Sons Ltd; 2020. pp. 1-9. doi: 10.1002/rmv.2141.

244	10.	Saito K, Sugawara H, Ichihara K, Watanabe T, Ishii A, Fukuchi T. Prediction of
245		72-hour mortality in patients with extremely high serum C-reactive protein levels using
246		a novel weighted average of risk scores. PLoS One. 2021;16: e0246259. doi:
247		10.1371/journal.pone.0246259.
248	11.	Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a
249		clinical risk score to predict the occurrence of critical illness in hospitalized patients
250		with COVID-19. JAMA Intern Med. 2020;180: 1081-1089. doi:
251		10.1001/jamainternmed.2020.2033.
252	12.	Xie J, Hungerford D, Chen H, Abrams ST, Li S, Wang G, et al. Development and
253		external validation of a prognostic multivariable model on admission for hospitalized
254		patients with COVID-19. SSRN J. doi: 10.2139/ssrn.3562456.
255	13.	Seifi S, Khatony A, Moradi G, Abdi A, Najafi F. Accuracy of pulse oximetry in
256		detection of oxygen saturation in patients admitted to the intensive care unit of heart
257		surgery: Comparison of finger, toe, forehead and earlobe probes. BMC Nurs. 2018;17:
258		15. doi: 10.1186/s12912-018-0283-1.
259	14.	Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between
260		inflammation and cancer. Vol. 26, In: Seminars in immunology. USA: Academic Press:
261		2014. pp. 54-74. doi: 10.1016/j.smim.2014.01.001.

262	15.	Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, et al.
263		Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
264		Cochrane Database Syst Rev. 2021;3: CD013881.
265	16.	Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al.
266		Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat
267		Med. 2022;28: 1785-1790. doi: 10.1038/s41591-022-01911-2.
268	17.	Baker JM, Nakayama JY, O'hegarty M, Mcgowan A, Teran RA, Bart SM, et al.
269		Morbidity and mortality weekly report SARS-CoV-2 B.1.1.529 (Omicron) variant
270		transmission within households-four U.S. Jurisdictions, 2022 [cited 2021 Nov].
271		Available from: https://www.cdc.gov/mmwr
272	18.	Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ,
273		et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of omicron
274		in South Africa. Science. 2022;376: eabn4947. doi: 10.1126/science.abn4947.
275	19.	Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al.
276		Comparative analysis of the risks of hospitalisation and death associated with
277		SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort
278		study. Lancet. 2022;399: 1303-1312. doi: 10.1016/S0140-6736(22)00462-7.

279	20.	Ebell MH, Hamadani R, Kieber-Emmons A. Development and validation of simple risk
280		scores to predict hospitalization in outpatients with COVID-19 including the omicron
281		variant. J Am Board Fam Med. 2022;35: 1058-1064. doi:
282		10.3122/jabfm.2022.220056R1.
283		



Figure